Attenuation of plasma low density lipoprotein cholesterol by select 3- hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in mice devoid of low density lipoprotein receptors

Journal of Lipid Research

Volumn 38, Issue 12, 1997, Pages 2502-2515

  Bisgaier, Charles L ^a   Essenburg, Arnold D ^a   Auerbach, Bruce J ^a   Pape, Michael E ^a   Sekerke, Catherine S ^a   Gee, Andrew ^a   Wölle, Sabine ^a   Newton, Roger S ^a  

^a PFIZER INC   (United States)

Author keywords

Atorvastatin; Lovastatin; Pravastatin; Simvastatin

Indexed keywords

APOLIPOPROTEIN B; APOLIPOPROTEIN B48; ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; TYLOXAPOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; FAMILIAL DISEASE; FEMALE; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN SECRETION; MALE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RECEPTOR UPREGULATION;

ANIMALS; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEINS B; CHOLESTEROL; CHOLESTEROL, LDL; FEMALE; HYDROXYMETHYLGLUTARYL COA REDUCTASES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOBLOTTING; LIPOPROTEINS; MALE; MICE; MICE, INBRED STRAINS; POLYETHYLENE GLYCOLS; RECEPTORS, LDL; RNA, MESSENGER; TIME FACTORS; TRIGLYCERIDES;

EID: 0031445149     PISSN: 00222275     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Brown, M. S., and J. L. Goldstein. 1986. A receptor-mediated pathway for cholesterol homeostasis. Science. 232: 34-37.
2. Goldstein, J. L., and M. S. Brown. 1989. Familial hypecholesterolemia. In The Metabolic Basis of Inherited Dieases. C. R. Scriver, A. L. Beaudet, W. S. Sly, and D. Valle, editors. McGraw-Hill, New York. 1215-1250.
3. Patsch, W., J. R. Patsch, and A. M. Gotto, Jr. 1989. The hyperlipoproteinemias. Med. Clin. North Am. 73: 859-893.
4. Davidson, B. L., E. D. Allen, K. F. Kozarsky, J. M. Wilson, and B. J. Roessler. 1993. A model system for in vivo gene transfer to the central nervous system using an adenoviral vector. Nature Genet. 3: 219-223.
5. Herz, J., and R. D. Gerard. 1993. Adenovirus-mediated transfer of low density lipoprotein receptor gene acutely accelerates cholesterol clearance in normal mice. Proc. Natl. Acad. Sci. USA. 90: 2812-2816.
6. Kozarsky, K., M. Grossman, and J. M. Wilson. 1993. Adenovirus-mediated correction of the genetic defect in hepatocytes from patients with familial hypercholesterolemia. Somat. Cell Mol. Gen. 19: 449-458.
7. Kozarsky, K. F., D. R. McKinley, L. L. Austin, S. E. Raper, L. D. Stratford-Rerricaudet, and J. M. Wilson. 1994. In vivo correction of low density lipoprotein receptor deficiency in the Watanabe heritable hyperlipidemic rabbit with recombinant adenoviruses. J. Biol. Chem. 269: 13095-13702.
8. Thompson, G. R. 1989. History and evolution of extracorporeal LDL elimination in severe hypercholesterolemia. Treatment of severe hypercholesterolemia in the prevention of coronary heart disease. Proceedings of the Second Symposium. 164-169.
9. Bilheimer, D. W., S. M. Grundy, M. S. Brown, and J. L. Goldstein. 1983. Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes. Proc. Natl. Acad. Sci. USA. 80: 4124-4128.
10. Reihnér, E., M. Rudling, D. Stahlberg, L. Berlund, S. Ewerth, I. Björkhem, K. Einarsson, and B. Angelin. 1990. Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol. N. Engl. J. Med. 323: 224-228.
11. Auerbach, B. J., B. R. Krause, C. L. Bisgaier, and R. S. Newton. 1995. Comparative effects of HMG-CoA reductase inhibitors on apoB production in the casein-fed rabbit: atorvastatin versus lovastatin. Atherosclerosis. 115: 173-180.
12. Grundy, S. M., and G. L. Vega. 1985. Influence of mevinolin on metabolism of low density lipoproteins in primary moderate hypercholesterolemia. J. Lipid. Res. 26: 1464-1475.
13. Vega, G. L., C. East, and S. M. Grundy. 1988. Lovastatin therapy in familial dysbetalipoproteinemia: effects on kinetics of apolipoprotein B. Atherosclerosis. 70: 131-143.
14. Vega, G. L., C. East, and S. M. Grundy. 1989. Effects of combined therapy with lovastatin and colestipol in heterozygous familial hypercholesterolemia. Effects on kinetics of apolipoprotein B. Arteriosclerosis. Supplement I 9: I-135-I-144.
15. Arad, Y., R. Ramakrishnan, and H. N. Ginsburg. 1990. Lovastatin therapy reduces low density lipoprotein apoB levels in subjects with combined hyperlipidemia by reducing the production of apoB-coniaining lipoproteins: implications for the pathophysiology of apoB production. J. Lipid. Res. 31: 567-582.
16. Arad, Y., R. Ramakrishnan, and H. N. Ginsburg. 1992. Effects of lovastatin therapy on very low density lipoprotein triglyceride metabolism in subjects with combined hyperlipidemia: evidence for reduced assembly and secretion of triglyceride-rich lipoproteins. Metabolism. 41: 487-493.
17. Shiomi, M., M. Shiraishi, T. Yata, and T. Ito. 1994. Effect of fluvastatin sodium on secretion of very low density lipoprotein and serum cholesterol levels. Arzneim.-Forsch./ Drug Res. 44(II),10: 1154-1156.
18. Davidson, N. O., S. Anant, and A. J. MacGinnitie. 1995. Apolipoprotein B messenger RNA editing: insights into the molecular regulation of post-transcriptional cytidine deamination. Curr. Opin. Lipidol. 6: 70-74.
19. Ishibashi, S., M. S. Brown, J. L. Goldstein, R. D. Gerard, R. E. Hammer, and J. Herz. 1993. Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J. Clin. Invest. 92: 883-893.
20. Ishibashi, S., J. L. Goldstein, M. S. Brown, J. Herz, and D. K. Burns. 1994. Massive xanthomatosis and atherosclerosis in cholesterol-fed low density lipoprotein receptor-negative mice. J. Clin. Invest. 93: 1885-1893.
21. Roth, B. D., C. J. Blankley, A. W. Chucholowski, E. Fergusin, M. E. Hoefle, D. F. Ortwine, R. S. Newton, C. S. Sekerke, D. R. Sliskovic, C. D. Stratton, and M. W. Wilson. 1991. Inhibitors of cholesterol biosynthesis. 3. Tetrahydro-4-hydroxy-6-[2-(1H-pyrrol-1-yl)ethyl]-2H-pyran-2-one inhibitors of HMG-CoA reductase. 2. Effects of introducing substituents at positions three and four of the pyrrole nucleus. J. Med. Chem. 34: 357-366.
22. Bocan, T. M. A., E. Ferguson, W. McNally, P. D. Uhlendorf, S. B. Mueller, P. Dehart, D. R. Sliskovic, B. D. Roth, B. R. Krause, and R. S. Newton. 1992. Hepatic and nonhepatic sterol synthesis and tissue distribution following administration of a liver specific HMG-CoA reductase inhibitor, CI-981: comparison with selected HMG-CoA reductase inhibitors. Biochim. Biophys. Acta. 1123: 133-144.
23. Allain, C. C., L. S. Poon, C. S. G. Chan, W. Richmond, and P. C. Fu. 1974. Enzymatic determination of total serum cholesterol. Clin. Chem. 20: 470-475.
24. Auerbach, B. J., J. S. Parks, and D. Applebaum-Bowden. 1990. A rapid and sensitive micro-assay for the enzymatic determination of plasma and lipoprotein cholesterol. J. Lipid. Res. 31: 738-742.
25. Kieft, K. A., T. M. A. Bocan, and B. R. Krause. 1991. Rapid on-line determination of cholesterol distribution among plasma lipoproteins after high-performance gel-filtration chromatography. J. Lipid. Res. 32: 859-866.
26. Aalto-Setälä, K., C. L. Bisgaier, A. Ho, K. A. Kieft, M. G. Traber, H. J. Kayden, R. Ramakrishnan, A. Walsh, A. H. Essenburg, and J. L. Breslow. 1994. Intestinal expression of human apolipoprotein A-IV in transgenic mice fails to influence dietary lipid absorption of feeding behavior. J. Clin. Invest. 93: 1776-1786.
27. Haubenwallner, S., A. D. Essenburg, B. C. Barnett, M. E. Pape, R. B. DeMattos, B. R. Krause, L. L. Minton, B. J. Auerbach, R. S. Newton, T. Leff, and C. L. Bisgaier. 1995. Hypolipidemic activity of select fibrates correlates to changes in hepatic apolipoprotein G-III expression: a potential physiologic basis for their mode of action. J. Lipid. Res. 36: 2541-2551.
28. Kita, T., M. S. Brown, and J. L. Goldstein. 1980. Feedback regulation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase in livers of mice treated with mevinolin, a competitive inhibitor of the reductase. J. Clin. Invest. 66: 1094-1100.
29. Chomczyski, P., and N. Sacchi. 1987. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162: 156-159.
30. Helmberg, A., R. Fassler, S. Geley, K. Johrer, G. Kroemer, G. Bock, and R. Kofler. 1990. Glucocorticoid-regulated gene expression in the immune system: analysis of glucocorticoid-regulated transcripts from the mouse macrophage like cell line P388D1. J. Immunol. 145: 4332-4337.
31. Rea, T. J., R. B. Demattos, and M. E. Pape. 1993. Hepatic-expression of genes regulating lipid metabolism in rabbits. J. Lipid Res. 34: 1901-1910.
32. Pape, M. E., G. W. Melchior, and K. R. Marotti. 1991. mRNA quantitation by a simple and sensitive RNAse protection assay. Genetic. Anal. 8: 206-213.
33. Otway, S., and D. S. Robinson. 1967. The use of a non-ionic detergent (Triton WR 1339) to determine rates of triglyceride entry into the circulation of the rat under different physiological conditions. J. Physiol. 190: 321-332.
34. Sirtori, C. R., P. Gomarasca, G. D'atri, S. Cerutti, G. Tronconi, and C. Scolastico. 1978. Pharmacological profile of BR-931, a new hypolipidemic agent that increases high-density lipoproteins. Artherosclerosis. 30: 45-56.
35. Towbin, H., T. Staehelin, and J. Gordon. 1979. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc. Natl. Acad. Sci. USA. 76: 4350-4354.
36. Harlow, E., and D. Lane. 1988. Immunoblotting. In Antibodies: A Laboratory Manual. Cold Spring Harbor Laboratory, New York. 471-510.
37. Ohtawa, M., and N. Uchiyama. 1992. Sex difference in metabolism of simvastatin by rat hepatic microsomes. Eur. J. Drug Metab. Pharmacokinet. 17: 175-181.
38. Greenspan, M. D., J. B. Yudkovitz, A. W. Alberts, L. S. Argenbright, B. H. Arison, and J. L. Smith. 1988. Metabolism of lovastatin by rat and human liver microsomes in vitro. Drug Metab. Dispos. 16: 678-682.
39. Vyas, K. P., P. H. Kari, S. M. Pitzenberger, R. A. Halpin, H. G. Ramjit, B. Arison, J. S. Murphy, W. F. Hoffman, M. S. Schwartz, E. H. Ulm, and D. E. Duggan. 1990. Biotransformation of lovastatin. I. Structure elucidation of in vitro and in vivo metabolites in the rat and mouse. Drug Metab. Dispos. 18: 203-211.
40. Vyas, K. P., P. H. Kari, S. R. Prakash, and D. E. Duggan. 1990. Biotransformation of lovastatin. II. In vitro metabolism by rat and mouse liver microsomes and involvement of cytochrome P-450 in dehydrogenation of lovastatin. Drug Metab. Dispos. 18: 218-222.
41. Ishibashi, S., J. Herz, N. Maeda, J. L. Goldstein, and M. S. Brown. 1994. The two-receptor model of lipoprotein clearance: tests of the hypothesis in "knockout" mice lacking the low density lipoprotein receptor, apolipoprotein E or both proteins. Proc. Natl. Acad. Sci. USA. 91: 4431-4435.
42. Rubinsztein, D. C., J. C. Cohen, G. M. Berger, D. R. van der Westhuyzen, G. A. Coetzee, and W. Gevers. 1990. Chylomicron remnant clearance from the plasma in familial hypercholesterolemic homozygotes with defined receptor defects. J. Clin. Invent. 86: 1306-1312.
43. Kita, T., J. L. Goldstein, M. S. Brown, Y. Watanabe, C. A. Hornick, and R. J. Havel. 1982. Hepatic uptake of chylomicron remnants in WHHL rabbits: a mechanism genetically distinct from the low-density lipoprotein receptor. Proc. Natl. Acad. Sci. USA. 79: 3623-3627.
44. Teng, B., C. F. Burant, and N. O. Davidson. 1993. Molecular cloning of an apolipoprotein B messenger RNA editing protein. Science. 260: 1816-1819.
45. Ginsberg, H. N. 1997. Role of lipid synthesis, chaperone proteins and proteasomes in the assembly and secretion of apoptotein B-containing lipoproteins from cultured liver cells. Clin. Exp. Pharmacol. Physiol. 24: A29-32.
46. Kozarsky, K. F., D. K. Bonen, F. Giannoni, T. Funahashi, J. M. Wilson, and N. O. Davidson. 1996. Hepatic expression of the catalytic subunit of the apolipoprotein B mRNA editing enzyme (apobec-1) ameliorates hypercholesterolemia in LDL receptor-deficient rabbits. Hem. Gene Ther. 7: 943-957.
47. Greeve, J., V. K. Jona, N. R. Chowdhury, M. S. Horwitz, and J. R. Chowdhury. 1996. Hepatic gene transfer of the catalytic subunit of the apolipoprotein B mRNA editing enzyme results in a reduction of plasma LDL levels in normal and Watanabe heritable hyperlipidemic rabbits. J. Lipid. Res. 37: 2001-2017.
48. Teng, B., S. Blumenthal, T. Forte, N. Navaratnam, J. Scott, A. M. Gotto, Jr., and L. Chan. 1994. Adenovirus-mediated gene transfer of rat apolipoprotein B mRNA-editing protein in mice virtually eliminates apolipoprotein B-100 and normal low density lipoprotein production. J. Biol. Chem. 269: 29395-29404.
49. Morrison, J. R., C. Paszty, M. E. Stevens, S. D. Hughes, T. Forte, J. Scott, and E. M. Rubin. 1996. Apolipoprotein B RNA editing enzyme-deficient mice are viable despite alterations in lipoprotein metabolism. Proc. Natl. Acad. Sci. USA. 93: 7154-7159.
50. Feher, M. D., J. G. Webb, D. D. Patel, A. F. Lant, P. D. Mayne, B. L. Knight, and A. K. Soutar. 1993. Cholesterol-lowering drug therapy in a patient with receptor-negative homozygous familial hypercholesterolemia. Atherosclerosis. 103: 171-180.
51. Naoumova, R. P., D. Marais, J. G. Firth, C. K. Y. Neuwirth, G. W. Taylor, and G. R. Thompson. 1996. Atorvastatin augments therapy of homozygous familial hypercholesterolemia by inhibiting upregulation of cholesterol synthesis after apheresis and bile acid sequestrants. Circulation (Suppl.). 94: I-583 (Abstract).